Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: The ELEMENT 1 study

Diabetes, Obesity and Metabolism

Volumn 17, Issue 8, 2015, Pages 726-733

  Blevins, T C ^a   Dahl, D ^b   Rosenstock, J ^c   Ilag, L L ^d   Huster, W J ^d   Zielonka, J S ^d   Pollom, R K ^d   Prince, M J ^d  

^a Texas Diabetes and Endocrinology   (United States)

^b Gründungsvorsitzender der Arbeitsgemeinschaft Diabetes und Migranten   (Germany)

^c DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Insulin glargine; LY2963016; Type 1 diabetes

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; LY2963016 INSULIN GLARGINE;

ADULT; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; ASTHMA; CONTROLLED STUDY; DERMATITIS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT ALLERGY; WEIGHT CHANGE; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION; DRUG EFFECTS; MEAL; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN ANTIBODIES; INSULIN GLARGINE; INSULIN LISPRO; MALE; MEALS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84937816371     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12496     Document Type: Article

References (30)

1. Johnson IS. Human insulin from recombinant DNA technology. Science 1983; 219: 632-637.
2. Krämer I, Sauer T. The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Br J Diabetes Vasc Dis 2010; 10: 163-171.
3. Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Nat Rev Drug Discov 2014; 13: 99-100.
4. European Medicines Agency. Marvel Life-Sciences Ltd withdraws its marketing authorisation applications for Insulin Human Rapid Marvel, Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel. EMEA/2435/2008. Press Release. 2008. Available from URL: www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015335.pdf. Accessed 15 October 2014.
5. European Medicines Agency. Marvel Life Sciences Ltd withdraws its marketing authorisation applications for Solumarv, Isomarv medium and Combimarv (human insulin). Press Release. 2012. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/11/WC500135156.pdf. Accessed 15 October 2014.
6. European Medicines Agency. Abasaglar (previously Abasria). 2014. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002835/human_med_001790.jsp&mid=WC0b01ac058001d124. Accessed 31 March 2015.
7. Food and Drug Administration. Drug Approval Package: Lantus (Insulin Glargine [rDNA Origin]). NDA #21-081 2000. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21081_Lantus.cfm. Accessed 31 March 2015.
8. Eli Lilly and Company. FDA grants tentative approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection). 2014. Available from URL: https://investor.lilly.com/releasedetail.cfm?ReleaseID=866751. Accessed 31 March 2015.
9. Food and Drug Administration. Biologics Price Competition and Innovation Act. 2009. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf. Accessed 31 March 2015.
10. European Medicines Agency. European public assessment report: Abasria. 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002835/WC500175383.pdf. Accessed 31 March 2015.
11. Hilgenfeld R, Seipke G, Berchtold H, Owens DR. The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs 2014; 74: 911-927.
12. Raskin P, Klaff L, Bergenstal R etal. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-1671.
13. Ratner RE, Hirsch IB, Neifing JL etal. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639-643.
14. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. 2005. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Accessed 31 March 2015.
15. World Health Organization. Expert Committee on biological standardization. Guidelines on evaluation of Similar Biotherapeutic Products (SBPs). 2009. Available from URL: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 31 March 2015.
16. Food and Drug Administration. Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product. 2014. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf. Accessed 31 March 2015.
17. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165988.pdf. Accessed 31 March 2015.
18. Byrd RA, Blackbourne JL, Schultze AE, Vahle JL. Comparative subchronic toxicity studies in rats of LY2963016 (LY), an insulin glargine product, with USA sourced Lantus® (US-L) and EU-sourced Lantus® (EU-L). Toxicologist 2014; 138: 1650.
19. Linnebjerg H, Quin Lam EC, Seger ME etal. Comparative pharmacokinetics (PK) and pharmacodynamics (PD) of LY2963016 insulin glargine and EU- and U.S.-approved versions of Lantus® insulin glargine in healthy subjects. Diabetes 2014; 63(Suppl. 1): 889-P.
20. Zhang X, Quin Lam EC, Seger ME etal. Comparative pharmacokinetics and pharmacodynamics of two insulin glargine products, LY2963016 and Lantus®, in healthy subjects at two dose levels. Diabetes 2014; 63(Suppl. 1): 890-P.
21. Heise T, Zhang X, Quin Lam EC etal. Duration of action of 2 insulin glargine products, LY2963016 and Lantus®, in subjects with type I diabetes mellitus (T1DM). Diabetes 2014; 63(Suppl. 1): 891-P.
22. Rosenstock J, Hollander P, Bhargava A, Ilag LL, Pollom RK, Zielonka JS, Huster WJ, Prince MJ (2015), Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes, Obesity and Metabolism. 2015; 17: 734-741.
23. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926.
24. Food and Drug Administration. Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft guidance February 2008. 2008. Available from URL: http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf. Accessed 1 April 2015.
25. Food and Drug Administration. Guidance for industry: non-inferiority clinical trials. Draft guidance March 2010. 2010. Available from URL: http://www.fda.gov/downloads/Drugs/&/Guidances/UCM202140.pdf. Accessed 1 April 2015.
26. European Medicines Agency. Guideline on the choice of the non-inferiority margin. 2005. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf. Accessed 15 October 2014.
27. Owens DR, Landgraf W, Schmidt A, Bretzel RG, Kuhlmann MK. The emergence of biosimilar insulin preparations-a cause for concern? Diabetes Technol Ther 2012; 14: 989-996.
28. European Medicines Agency. LANTUS: EPAR - Product information. 2015. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000284/WC500036082.pdf. Accessed 1 April 2015.
29. U.S. National Library of Medicine. LANTUS- insulin glargine injection, solution. Drug label information. 2015. Available from URL: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5e07a0c-7e14-4756-9152-9fea485d654a. Accessed 1 April 2015.
30. Linnebjerg H, Lam ECQ, Seger ME etal. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus® insulin glargine in healthy subjects: 3 randomized euglycemic clamp studies (under review). 2015.